Table 6 |
||||
|
KEGG pathways containing target proteins or their interacting partners |
||||
|
Pathway Name |
Corrected p-value |
Number of target proteins selected |
Total number of proteins in pathway |
Fraction of population as targets |
|
MAP kinase signaling pathway |
4.26E-05 |
19 |
259 |
0.073 |
|
Antigen processing and presentation |
6.66E-05 |
10 |
80 |
0.125 |
|
Alzheimer's disease |
1.11E-04 |
6 |
28 |
0.214 |
|
Long-term potentiation |
5.78E-04 |
8 |
65 |
0.123 |
|
Neurodegenerative disorders |
0.0011 |
6 |
39 |
0.154 |
|
Long-term depression |
0.0018 |
8 |
75 |
0.107 |
|
Arginine and proline metabolism |
0.0018 |
7 |
34 |
0.201 |
|
Adipocytokine signaling pathway |
0.0054 |
7 |
73 |
0.096 |
|
|
||||
|
Fang et al. BMC Chemical Biology 2009 9:5 doi:10.1186/1472-6769-9-5 |
||||
